| 1 | previous | 20,890 |
| 2 | molecular-genetic | 5 |
| 3 | postrehabilitation | 5 |
| 4 | iscomatrix™ | 3 |
| 5 | pervious | 3 |
| 6 | cochrane-style | 2 |
| 7 | gh-deficiency | 2 |
| 8 | meta-analyses.this | 2 |
| 9 | part-time/full-time | 2 |
| 10 | stage-adapted | 2 |
| 11 | stress-trained | 2 |
| 12 | tj- | 2 |
| 13 | two-to-five | 2 |
| 14 | 13,498 | 1 |
| 15 | 13,502 | 1 |
| 16 | 147,774 | 1 |
| 17 | 294,159 | 1 |
| 18 | 5,503 | 1 |
| 19 | 5/672 | 1 |
| 20 | arm-training | 1 |
| 21 | bioinformatic-driven | 1 |
| 22 | ckd.eight | 1 |
| 23 | ckd.three | 1 |
| 24 | electrifying | 1 |
| 25 | electroretinographics | 1 |
| 26 | full-time/part-time | 1 |
| 27 | histo-pathologic | 1 |
| 28 | htn.hypertension | 1 |
| 29 | medline/embase/conference | 1 |
| 30 | nonindustry-funded | 1 |
| 31 | nonoffice | 1 |
| 32 | ohione | 1 |
| 33 | partial=1-29 | 1 |
| 34 | placebo.fourteen | 1 |
| 35 | placebo.twenty-seven | 1 |
| 36 | placebo.two | 1 |
| 37 | poly-user | 1 |
| 38 | pregnancies.four | 1 |
| 39 | proliferate-because | 1 |
| 40 | psychoproteomics | 1 |
| 41 | review.seventeen | 1 |
| 42 | since.four | 1 |
| 43 | soccer-playing | 1 |
| 44 | ssi/uti | 1 |
| 45 | statin/low-dose | 1 |
| 46 | vaso-proliferative | 1 |
| 1 | 13,498 | 1 |
| 2 | 13,502 | 1 |
| 3 | 147,774 | 1 |
| 4 | 294,159 | 1 |
| 5 | 5,503 | 1 |
| 6 | 5/672 | 1 |
| 7 | arm-training | 1 |
| 8 | bioinformatic-driven | 1 |
| 9 | ckd.eight | 1 |
| 10 | ckd.three | 1 |
| 11 | cochrane-style | 2 |
| 12 | electrifying | 1 |
| 13 | electroretinographics | 1 |
| 14 | full-time/part-time | 1 |
| 15 | gh-deficiency | 2 |
| 16 | histo-pathologic | 1 |
| 17 | htn.hypertension | 1 |
| 18 | iscomatrix™ | 3 |
| 19 | medline/embase/conference | 1 |
| 20 | meta-analyses.this | 2 |
| 21 | molecular-genetic | 5 |
| 22 | nonindustry-funded | 1 |
| 23 | nonoffice | 1 |
| 24 | ohione | 1 |
| 25 | part-time/full-time | 2 |
| 26 | partial=1-29 | 1 |
| 27 | pervious | 3 |
| 28 | placebo.fourteen | 1 |
| 29 | placebo.twenty-seven | 1 |
| 30 | placebo.two | 1 |
| 31 | poly-user | 1 |
| 32 | postrehabilitation | 5 |
| 33 | pregnancies.four | 1 |
| 34 | previous | 20,890 |
| 35 | proliferate-because | 1 |
| 36 | psychoproteomics | 1 |
| 37 | review.seventeen | 1 |
| 38 | since.four | 1 |
| 39 | soccer-playing | 1 |
| 40 | ssi/uti | 1 |
| 41 | stage-adapted | 2 |
| 42 | statin/low-dose | 1 |
| 43 | stress-trained | 2 |
| 44 | tj- | 2 |
| 45 | two-to-five | 2 |
| 46 | vaso-proliferative | 1 |
| 1 | tj- | 2 |
| 2 | 13,502 | 1 |
| 3 | 5/672 | 1 |
| 4 | 5,503 | 1 |
| 5 | 147,774 | 1 |
| 6 | 13,498 | 1 |
| 7 | partial=1-29 | 1 |
| 8 | 294,159 | 1 |
| 9 | histo-pathologic | 1 |
| 10 | molecular-genetic | 5 |
| 11 | nonindustry-funded | 1 |
| 12 | stress-trained | 2 |
| 13 | stage-adapted | 2 |
| 14 | nonoffice | 1 |
| 15 | medline/embase/conference | 1 |
| 16 | ckd.three | 1 |
| 17 | cochrane-style | 2 |
| 18 | part-time/full-time | 2 |
| 19 | full-time/part-time | 1 |
| 20 | ohione | 1 |
| 21 | statin/low-dose | 1 |
| 22 | proliferate-because | 1 |
| 23 | two-to-five | 2 |
| 24 | vaso-proliferative | 1 |
| 25 | arm-training | 1 |
| 26 | soccer-playing | 1 |
| 27 | electrifying | 1 |
| 28 | ssi/uti | 1 |
| 29 | review.seventeen | 1 |
| 30 | placebo.fourteen | 1 |
| 31 | placebo.twenty-seven | 1 |
| 32 | bioinformatic-driven | 1 |
| 33 | htn.hypertension | 1 |
| 34 | postrehabilitation | 5 |
| 35 | placebo.two | 1 |
| 36 | poly-user | 1 |
| 37 | since.four | 1 |
| 38 | pregnancies.four | 1 |
| 39 | electroretinographics | 1 |
| 40 | psychoproteomics | 1 |
| 41 | meta-analyses.this | 2 |
| 42 | previous | 20,890 |
| 43 | pervious | 3 |
| 44 | ckd.eight | 1 |
| 45 | gh-deficiency | 2 |
| 46 | iscomatrix™ | 3 |